GenEdit, Inc., a biotechnology company with a mission to develop curative therapies through targeted in vivo delivery of genetic medicines, today announced that it has closed a $26 million Series A financing. New investors Eli Lilly, KTB Network, Ltd., Company K Partners, Korea Investment Partners, DAYLI Partners, KB Investment, IMM Investment, and TIMEFOLIO Asset Management, join existing investors DCVC Bio, SK Holdings, Bow Capital, and Sequoia Capital, participating in the financing. The funding will support the further development of GenEdit’s NanoGalaxyTM platform of non-viral, non-lipid polymer nanoparticles, and the selection for clinical development of therapeutic candidates targeting diseases of the nervous system.